In Pancreatic Cancer, Blood Neutrophil-Lymphocyte Ratio Predicts Survival
the Cancer Therapy Advisor take:
Baseline and post-chemotherapy neutrophil-lymphocyte ratio (NLR) change are potential biomarkers for overall survival in patients with advanced pancreatic cancer undergoing chemotherapy, according to a study published in the Annals of Surgical Oncology.
Researchers at the Fudan University Shanghai Cancer Center in China retrospectively examined 403 patients who had undergone chemotherapy for advanced pancreatic adenocarcinoma from 2002 to 2013. They wanted to determine the prognostic role of NLR in these patients.
The researchers performed univariate and multivariate analyses in order to identify clinicopathological predictors of overall survival that included baseline NLR and post-chemotherapy NLR.
They found that both baseline NLR and post-chemotherapy NLR change were independent prognostic factors in overall survival.
NLR of 3.1 or greater before chemotherapy as well as NLR post-chemotherapy change were both significantly associated with distant metastasis, serum CA19-9 levels and serum albumin levels.
NLR change is a potential biomarker for survival in advanced pancreatic cancer.
From Mdlinx
Related Resources
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Prostate Cancer | Regimens | Drugs |
| Rare Cancers | Regimens | |
| Renal Cell Carcinoma | Regimens | Drugs |
| Skin Cancer | Regimens | Drugs |
| Urologic Cancers | Regimens | Drugs |
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Chemotherapy Plays a Role in Skeletal Muscle Atrophy in Patients With Breast Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Lenalidomide Induces Immunity, Produces Clinical Response in CLL
- Comorbidities Signal Worse Outcomes in CLL After Targeted Treatment
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia
